
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics is well-positioned for growth due to positive momentum in gaining coverage for their EsoGuard test, exceeding targets for 8 consecutive quarters, upcoming Medicare coverage, and the effectiveness of their test in detecting esophageal cancer. With a non-invasive device, inclusion in medical guidelines, and potential revenue backlog of $40 million, the company has significant potential for growth. However, potential delays in Medicare payment and reimbursement issues are important risks to keep in mind.
Bears say
Lucid Diagnostics is facing long-term commercialization and growth challenges, but has had some success with obtaining positive payer coverage for its EsoGuard product. However, its $47 million cash balance and $22 million in debt may not be sufficient to sustain the company through 2027, which presents a high risk for investors. Additionally, the current valuation of the company may not fully reflect these risks and the potential for upside.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares